GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to www.seekgmp.com FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

  • This is default featured slide 1 title

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • GMP Trends, Quality Tools

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • GMP News drifts on Market and economy

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • This is default featured slide 4 title

    Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

  • What to Ask Your Doctor Before Taking Opioids

    Every patient should ask questions when getting a new prescription. This is especially important when your doctor, dentist or other health care professional prescribes you an opioid, such as hydrocodone, oxycodone, codeine and morphine. What should you ask?

Showing posts with label FEB17. Show all posts
Showing posts with label FEB17. Show all posts

Monday, February 27, 2017

GMP Violations @ Specifications | Testings | Follow written procedures | Prevent mix-ups |











This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See 21 CFR, parts 210 and 211.

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).


During our inspection, our investigator observed specific violations including, but not limited to, the following.

1.    Your firm does not have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).

For example, you have not tested any of the (b)(4) patches you manufacture to determine the identity, purity, or potency of each active ingredient prior to release.

2.    Your firm failed to test samples of each component for conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(2)).

For example, you have not tested incoming active pharmaceutical ingredients or other components you use in manufacturing (b)(4) patches to determine their identity, purity, and potency.

3.    Your firm failed to establish and follow written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).

For example, you did not have cleaning procedures for the manufacturing equipment you use to make (b)(4) patches. During the inspection, our investigator observed rust and unidentified (b)(4) residue on your (b)(4) and other manufacturing equipment.

4.    Your firm failed to establish written procedures to prevent mix-ups and cross contamination by physical or spatial separation from operations on other drug products (21 CFR 211.130(a)).

For example, our investigator observed (b)(4) of unlabeled (b)(4) patches of different sizes and colors co-mingled on a table awaiting final packaging, which could lead to product mix-ups during packaging operations.

5.    Your firm delayed, denied, or limited an inspection, or refused to permit the FDA inspection.

You limited FDA’s inspection because you refused to provide FDA with records related to suppliers of components and products that you repackage at your facility. 

Although you provided the names of two of your suppliers, you refused to provide documentation to show the identities of components or products you obtained from these suppliers, or whether these suppliers performed appropriate release testing on the materials before you received them. Refusing to provide records requested by the FDA investigator that FDA has authority to inspect is considered limiting an inspection.

When an owner, operator, or agent delays, denies, limits, or refuses an inspection, the drugs may be deemed adulterated under section 501(j) of the FD&C Act. See FDA’s guidance, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection, available online at  www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM360484.pdf.
 

FDA Sampling and Testing of your Products

FDA collected samples of your product during an inspection of a customer’s facility. FDA tested  samples of (b)(4) ((b)(4) ointment (b)(4)%). FDA laboratory analysis showed that they samples of your product were sub-potent for the labeled active ingredient, containing an average potency of 69.0% of the label claim.

Consultant Recommended

In your response to the Form FDA 483, you committed to (b)(4). In addition, you committed to engaging a contract laboratory to test drug products distributed to the United States in 2016, and you provided some reports of test results. However, the reports you provided are inadequate because they omit critical information about the tests your contract laboratory performed, such as relevant drug product specifications, and details about the methods used.


Conclusion

Violations cited in this letter are not intended as an all-inclusive list. You are responsible for investigating these violations, for determining the causes, for preventing their recurrence, and for preventing other violations.


Source: FDA
www.gmpviolations.com
 GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
Share:

Sunday, February 26, 2017

India's NRA for medicines is lauded by WHO

India's NRA for medicines is lauded by WHO
J P Nadda, Union Minister for Health & Family Welfare

In a letter to J P Nadda, Union Minister for Health & Family Welfare, the WHO applauded the country's NRA, declaring it "functional' with a maturity level of 4 -- the highest level as per currently evolved definitions in respect of 5 functions -- and maturity level 3 in respect of 4 functions. While, maturity level 4 indicates good results and sustained improvement trends, maturity level 3 reflects systematic process based approach, early stage of systematic improvements, data availability regarding conformance to objectives and existence of improvement trends.
Share:

Wednesday, February 22, 2017

GMP violations with respective to cGMP Practices @ FDA Warning letter











The U.S. Food and Drug Administration (FDA) inspected Chinese firm M/s Baoying County Fukang Medical Appliance Co. revealed serious 6 GMP Violations. Details as below
Share:

Global health leaders meet in Sri Lanka to discuss and reset the agenda on Migrant Health & World Health Organization (WHO)



Feb 22, Colombo: Global health leaders meet in Colombo, Sri Lanka, this week to discuss the migrant health and reset the agenda on migrant health based on the current trends of global migration.
Share:

Tuesday, February 21, 2017

Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry


The FDA has published the Guidance for Industry "Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification".
Share:

Thursday, February 16, 2017

Baxter Healthcare Corporation To Pay More Than $18 Million To Resolve Criminal And Civil Liability Relating To Sterile Products

Image result for Baxter Healthcare Corporation


Company Failed to Follow Good Manufacturing Practices in North Carolina Facility
WASHINGTON - Healthcare company Baxter Healthcare Corporation (Baxter) has agreed to pay $18.158 million to resolve its criminal and civil liability arising from Baxter’s failure to follow current Good Manufacturing Practices (cGMP) when manufacturing sterile drug products in North Carolina, the Department of Justice announced. The resolution includes a deferred prosecution agreement and penalties and forfeiture totaling $16 million and a civil settlement under the False Claims Act (FCA) with the federal government totaling approximately $2.158 million. Baxter is a Delaware corporation and subsidiary of Baxter International Inc., headquartered in Deerfield, Illinois, with many manufacturing facilities throughout the United States and the world, including one in Marion, North Carolina (North Cove).

In a criminal information filed in the Western District of North Carolina, the government charged that, between July 2011 and November 2012, Baxter introduced into interstate commerce drugs that were adulterated under the Federal Food, Drug, and Cosmetic Act (FDCA) because Baxter did not follow cGMP when making those products. At North Cove, Baxter manufactured large-volume sterile intravenous (IV) solutions in a clean room that had high-efficiency particulate absorption (HEPA) filters installed in the ceiling. Air was pushed into the clean room through the HEPA filters. As alleged in the information, during the relevant time period, a Baxter employee reported the presence of mold on the HEPA filters to plant management. However, Baxter continued to manufacture IV solutions in that clean room for months while the filters the employee had identified as moldy remained in place. Subsequent testing of the filters following an unannounced U.S. Food and Drug Administration (FDA) inspection revealed several mold species on the filters. There was no evidence of impact on the IV solutions from the mold found on the filters.

In a deferred prosecution agreement to resolve the charge, Baxter admitted that it distributed products in interstate commerce that were adulterated in violation of the FDCA. Under the terms of the deferred prosecution agreement, Baxter will pay a total of $16 million in monetary penalties and forfeiture and will implement enhanced compliance provisions, including periodic certifications to the government concerning its implementation of those provisions. The deferred prosecution agreement will not be final until accepted by the U.S. District Court.

“Following current Good Manufacturing Practices is essential to ensure the safety and efficacy of our drugs,” said Principal Deputy Assistant Attorney General Benjamin C. Mizer, head of the Justice Department’s Civil Division. “Today’s settlement shows that the government will continue to hold companies accountable for failing to fulfill this critically important responsibility.”

“Despite notification by an employee of potential contamination concerns, Baxter was poorly focused on instituting sufficient safety standards for their products,” said U.S. Attorney Jill Westmoreland Rose for the Western District of North Carolina (WDNC). “Today’s resolution reflects WDNC’s commitment to hold accountable drug companies that violate manufacturing standards and wrongly profit from those violations.”

“FDA’s manufacturing standards are designed to ensure the quality, safety, and efficacy of drugs distributed to American consumers, and FDA expects pharmaceutical companies to correct deficiencies in an expedited manner,” said Special Agent in Charge Justin Green of FDA’s Office of Criminal Investigations, Miami Field Office. “We will remain vigilant in our efforts to protect the U.S. public health from potentially dangerous products.”

In addition, Baxter will pay approximately $2.158 million to resolve allegations that the company violated the FCA by submitting false claims to the Department of Veterans Affairs based upon Baxter’s failure to follow cGMPs.

The civil settlement resolves a lawsuit filed by Christopher Wall, an employee of Baxter, under the whistleblower provision of the False Claims Act, which permits private parties to file suit on behalf of the United States for false claims and share in a portion of the government’s recovery. The civil lawsuit was filed in the Western District of North Carolina and is captioned United States ex rel. Christopher Wall v. Baxter International, Inc. et al., No. 13cv42 (W.D.N.C.). Mr. Wall will receive $431,535.99 from the proceeds of the civil settlement.

This settlement illustrates the government’s emphasis on combating health care fraud and marks another achievement for the Health Care Fraud Prevention and Enforcement Action Team (HEAT) initiative, which was announced in May 2009 by the Attorney General and the Secretary of Health and Human Services. The partnership between the two departments has focused efforts to reduce and prevent Medicare and Medicaid financial fraud through enhanced cooperation. One of the most powerful tools in this effort is the False Claims Act. Since January 2009, the Justice Department has recovered a total of more than $31.4 billion through False Claims Act cases, with nearly $19.6 billion of that amount recovered in cases involving fraud against federal health care programs.

The settlement with Baxter was the result of a coordinated effort among the U.S. Attorney’s Office for the Western District of North Carolina and the Civil Division’s Consumer Protection Branch and Commercial Litigation Branch, with assistance from the FDA’s Office of Chief Counsel. The criminal investigation was conducted by the FDA’s Office of Criminal Investigations.

Except as to conduct admitted in connection with the deferred prosecution agreement, the claims settled by the civil agreement are allegations only and there has been no determination of civil liability.

For more information about the Consumer Protection Branch and its enforcement efforts, visit its website at http://www.justice.gov/civil/consumer-protection-branch. For more information on the Commercial Litigation Branch’s Fraud Section, visit https://www.justice.gov/civil/fraud-section. For more information about the U.S. Attorney’s Office for the Western District of North Carolina, visit https://www.justice.gov/usao-wdnc.
www.gmpviolations.com
 GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
Share:

Friday, February 10, 2017

Aurobindo Pharma to set up vaccine manufacturing facility




The company has formed a joint venture (JV) with the Hyderabad-based Tergene Biotech Private Limited, a vaccine development company, for developing pneumococcal conjugate vaccine.

Drug maker Aurobindo Pharma will set up a facility to manufacture 50 million dosages of vaccines per annum as it plans to launch its vaccine products commercially in 2018. Vaccines segment is another addition to the company’s differentiated portfolio where there are unmet needs and limited competition, Aurobindo Pharma said in its annual report. The company has formed a joint venture (JV) with the Hyderabad-based Tergene Biotech Private Limited, a vaccine development company, for developing pneumococcal conjugate vaccine (PCV). Tergene is currently working on development of the PCV.
PCV is a commercially available vaccine with limited competition and a global branded market of more than USD 6 billion, it said. “Aurobindo will hold a majority stake in the JV (with Targene Biotech) and will fund the product development in a phased manner spanning over three years. Development work for a few more products has commenced towards building a sizable vaccines portfolio. Toxicology studies have been completed.
“A cGMP pilot plant for clinical lot manufacture is ready and we are now working on clinical trial protocols. The plans are to create infrastructure for 50 million dosage per annum, with the first phase launch being targeted for 25 million doses. All these efforts are being synchronised to achieve commercial launch of Aurobindo’s branded products in 2018,” the company said in its annual report.
It, however, did not disclose information related to location of the manufacturing facility. The company is also in the process of developing a wide range of oncology and hormonal products which would include vials (wet vials and dry vials), prefilled syringes, capsules and tablets that are used in the hospital as well as in oncology and renal clinics, the report said.
“A new R&D centre dedicated for generic research in the field of oncology and hormones has been set up at Hyderabad to develop anticancer drugs and hormonal products, both for solid and parenteral dosage forms. The oral, solid dose formulations sections of oncology and hormone manufacturing facility has been completed and commissioned.
“The injectable areas of oncology facility are expected to be commissioned in later part of 2016. We have selected over 50 oncology products in our portfolio and plans are to initiate the exhibit batches for more than 15 products in 2016-17 and the dossier filing in regulated markets are expected to be initiated in early 2017,” Aurobindo said.
The drug maker also said a new block to manufacture oncology API is being added keeping the future requirements, and the facility is expected to be operational in 2017-18.
Shared under: Pharma News
Source: Indianexpress
www.gmpviolations.com
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
Share:

Thursday, February 9, 2017

PDA Position Paper: A Call For Reform In Global Post-Approval Change Processes





By the PDA Post Approval Change: 
Innovation for Availability of Medicines (PAC iAMSM) Task Force*


The seamless delivery of high quality, effective, and safe medicines to patients is each drug company’s ultimate duty. However, providing medication to patients is by no means effortless, as evidenced by the drug product shortage listings on health authority websites. The availability of medicines is challenged by a variety of factors, one of which is global supply chain segmentation due to global regulatory hurdles imposed on product related post-approval changes (PACs).

Share:

What are the current GMP Inspection Initiatives?

What are the current GMP Inspection Initiatives?

The International Coalition of Medicines Regulatory Authorities (ICMRA) has published a very interesting overview about the current global GMP inspection initiatives by the competent authorities. It also shows the various initiatives between the EU and the US Food and Drug Administration (FDA):
EMA/FDA/TGA API Programme
This programme of the European Medicines Agency (EMA), the European Directorate of the Quality of Medicines and Healthcare (EDQM), the European National Supervisory Authorities, the US Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and the World Health Organization (WHO) tries to foster the cooperation and mutual confidence between the participants through better communication and exchange of information on inspection planning. It covers joint inspections of API manufacturers located outside the participating regions but also the reliance on API inspections by other authorities.
EMA/FDA Mutual reliance Confidence building
The overall objective of this initiative is to allow some inspections on each others’ territories to be deferred or waived completely based on a number of considerations.
EMA/FDA Finished Products programme
This programme is closely related to the one above. Here, EMA and FDA are evaluating whether greater international collaboration can help to better distribute inspection capacity, allowing more sites to be monitored and reducing unnecessary duplication, limited to inspections of manufacturers of human medicinal (finished drug) products which come under the authority of FDA’s Center for Drug Evaluation and Research and the centralised marketing authorisation process in the EU.
PIC/S Pharmaceutical Inspection Co-operation Scheme
Inspectorates from various EU Member States and the FDA are member of PIC/S which tries to foster the international co-operation in the field of GMP by developing and promoting harmonised GMP standards and guidance documents, training GMP inspectors, assessing (and reassessing) GMP inspectorates and facilitating co-operation and networking and planning of inspection.
The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, executive-level, strategic coordinating, advocacy and leadership entity of regulatory authorities that work together to
  • address current and emerging human medicine regulatory and safety challenges globally, strategically and in an ongoing, transparent, authoritative and institutional manner
  • provide direction for areas and activities common to many regulatory authorities’ missions
  • identify areas for potential synergies
  • wherever possible, leverage existing initiatives/enablers and resources
ICMRA wants to provide a global architecture to support enhanced communication, information sharing, crisis response and address regulatory science issues.
Source: ICMRA & GMP compliance news
www.gmpviolations.com
GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
Share:

What is the ICMRA?

What is the ICMRA?
The ICMRA is a venue for heads of national regulatory authorities around the world to enable a shared strategic leadership to address current and emerging global regulatory challenges and to better leverage resources in ways that expand global regulatory reach.
Share:

Tuesday, February 7, 2017

India’s measles-rubella vaccination campaign a big step towards reducing childhood mortality, addressing birth defects

WHO NEWS













By Dr Poonam Khetrapal Singh, WHO Regional Director for South-East Asia

World Health Organization congratulates India for launching one of the world’s largest vaccination campaign against measles, a major childhood killer disease, and congenital rubella syndrome (CRS), responsible for irreversible birth defects.
The campaign launched today to vaccinate more than 35 million children in the age group of nine months to 15 years with MR (measles and rubella) vaccine, once again demonstrates India’s commitment to improve health and well-being of its people by protecting children against vaccine preventable diseases.
The first phase of the campaign is significant as it is expected to accelerate the country’s efforts to eliminate measles which affects an estimated 2.5 million children every year, killing nearly 49 000 of them. The campaign also marks the introduction of rubella vaccine in India’s childhood immunization programme to address CRS which causes birth defects such as irreversible deafness and blindness in nearly 40 000 children every year.
India has made important efforts and gains against measles in recent years. Measles deaths have declined by 51% from an estimated 100 000 in the year 2000 to 49 000 in 2015. This has been possible by significantly increasing the reach of the first dose of measles vaccine, given at the age of nine months under routine immunization programme, from 56% in 2000 to 87% in 2015. In 2010 India introduced the second dose of measles-containing vaccine in routine immunization programme to close the immunity gap and accelerate measles elimination. Nearly 118 million children aged nine months to 10 years were vaccinated during mass measles vaccination campaigns between 2010 and 2013 in select states of India.
Today’s campaign, the first in the series to cover a total of 410 million children across the country over the next 2 years, is a truly remarkable, world-beating effort. Apart from improving the life-chances of millions of children in India, the campaign is expected to have a substantial effect on global measles mortality and rubella control target as India accounts for 37% of global measles deaths.
For the MR campaign to be effective, it is important that throughout its duration, and in routine immunization thereafter, no child is left behind.
Simultaneously, India continues to further strengthen surveillance for measles and rubella, an important learning from India’s polio eradication programme that helped to identify infected and vulnerable areas and populations and enabled the programme adopt appropriate strategies to eradicate the disease.
India has already beaten smallpox, polio, maternal and neonatal tetanus and, very recently, yaws. Further gains in the battle against measles will help achieve a number of other public health priorities.

A regional flagship of WHO in South-East Asia, elimination of measles will contribute to achieving Sustainable Development Goal’s target 3.2 which, among others, aims to end preventable deaths of newborns and children under five years of age by 2030


Source: WHO
Published under: Health News

www.gmpviolations.com

 GMP News, GMP guidelines, GMP Violations, GMP warnings, GMP Trends. A Public Health Global News Portal. (This story has not been edited by GMP Violations staff and is auto-generated from a syndicated feed.) Disclaimer: The Logos/Images & content posted here are belongs to respective to Authority / owners of firm. The Article posted under public health importance news.
Share:

Monday, February 6, 2017

Trump order on regulations could create hurdles for FDA, Reconsider Annual Compliance Costs












WASHINGTON — President Trump on Monday signed an executive order directing federal agencies to cut two regulations for every new one that they adopt, a move that could have significant implications for the Food and Drug Administration. 
Share:

Saturday, February 4, 2017

FDA cGMP violations and Quality assurance has took failure decisions


















With this article we would like to share you about 2 of 4 FDA cGMP violations which teach about cGMP from where non GMP activities went. (Click here to read about observation 1 of 4) 

Learn observation 2: The inspector has identified that the API product has been released without testing mandatory tests.

Share:

Friday, February 3, 2017

FDA cGMP violations which teach about cGMP from where non GMP activities went. Learn about effective CAPA system



























FDA cGMP violations which teach about cGMP from where non GMP  activities went. Learn about effective CAPA system .

Share:

Wednesday, February 1, 2017

European Medicines Agencies and PIC/S agree on Audit Cooperation


 PIC/S & EMA


















PIC/S has published a "Letter of Agreement between the EEA Heads of Medicines Agencies and the Pharmaceutical Inspection Co-operation Scheme" on their website. The objective of the agreement is the exchange of information after audits among authorities and joint trainings for GxP inspectors.
Share:
Related Posts Plugin for WordPress, Blogger...

Popular Posts

Related Posts Plugin for WordPress, Blogger...

Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner

Followers

Printfriendly

Subscribe via email for free

Services

Enter your email address:

Delivered by FeedBurner

Contact Form

Name

Email *

Message *

Menu :
Powered by Blogger.

Visitors

    Translater

    Category

    2016 (37) 2017 (85) 2018 (10) 211 CFR (2) 211.63 (1) 21cfr (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (73) FDA Guide (20) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (40) MAR17 (13) Mar18 (7) May17 (10) May18 (1) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (44) WHO (6) zika (1)

    Sponsors

    Theme Support